Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$10.49 USD
+0.51 (5.11%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $10.31 -0.18 (-1.72%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Summit Therapeutics PLC [SMMT]
Reports for Purchase
Showing records 21 - 40 ( 40 total )
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
3Q19 Update; Ri-CoDIFy Phase 3 Enrollment Gradually Ramping Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Updated Thoughts Post R-D Day and 2Q19 Earnings
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Playing a Waiting Game; Modest Model Update Post FY18 Earnings
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Model Update and Recent Corporate Developments; Target Lowered to $2 to Reflect Increased Share Count
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Getting it Wrong Hurts; Summit Now Leveraged to Phase 3 Ready Ridilinazole; Target Lowered to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
FDA and CMS Trying to Make Anti-infectives Investable Again; Just as Summit Ramps its Antibacterial Efforts
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Should We Be Expecting Fireworks in July?
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Handicapping the Stock Move Post PhaseOut DMD Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
The Upcoming PhaseOut DMD Readout Could Be a Potential Watershed Moment
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Taking a Modest Leap of Faith, Increasing Price Target to $20; Awaiting More Clarity From the 48-Week Readout in 3Q18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Oral Systemic Therapy for DMD is a Hard Nut to Crack;First Look at PhaseOut DMD Provides a Mixed Bag
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Transforming Into an Anti-Infective Company, But Will the Street Care?
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Summiting Mount Utrophin; Assuming Coverage With a Buy and $16 Target
Provider: H.C. Wainwright & Co., Inc.
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Several Positive Announcements; Reiterate Our Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
Summit Seals Ex US Collaboration With Sarepta; Reiterate Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Summit Therapeutics PLC
Industry: Medical - Drugs
We are initiating with a Buy and a $26.00 12-month price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C